TheEdgeResearch
Home / Stocks / SLGC

SomaLogic, Inc. (SLGC)

NASDAQ Healthcare Medical - Healthcare Information Services
$2.10 ▼ -4.55%
Market Cap
$396.2M
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Beta
1.64
52-Wk Range
1.73-3.79
CEO
Stephen A. Williams BS, MB,
Country
US
Currency
USD

SomaLogic, Inc. operates in the Medical - Healthcare Information Services industry of the Healthcare sector, headquartered in Boulder, CO, US. The stock last traded at $2.10, down 4.55% on the session, giving a market capitalisation of $396.2M. On trailing twelve-month figures it carries a trailing P/E of -3.56, a net margin of -111.8%. Its beta of 1.64 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-3.56
Price / Sales
4.06
Price / Book
0.69
EV / EBITDA
0.13
Gross margin
55.6%
Operating margin
-180.0%
Net margin
-111.8%
Return on equity
Debt / equity
0.00
Current ratio
13.42
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
451
IPO date
2021-04-23
Headquarters
Boulder, CO, US
About SomaLogic, Inc.

SomaLogic, Inc. is a U.S.-based enterprise specializing in the identification of protein biomarkers and the development of clinical diagnostic solutions. A core aspect of its technology involves the creation of slow off-rate modified aptamers (SOMAmers) – unique nucleic acid-based reagents meticulously designed to specifically bind with their target proteins. The company also provides its proprietary SomaScan services, which enable the simultaneous detection and precise quantification of numerous proteins within intricate biological samples. This integrated SOMAmer and SomaScan platform empowers researchers to analyze diverse biological specimens, uncovering protein biomarker signatures invaluable for pharmaceutical discovery and development initiatives. Furthermore, the biomarker insights gleaned from SomaScan are instrumental in developing diagnostic applications across a range of conditions, such as cardiovascular and metabolic diseases, nonalcoholic steatohepatitis (NASH), and for general wellness monitoring. SomaLogic additionally furnishes SomaSignal tests, available for both research use only (RUO) and as laboratory-developed tests (LDTs). The firm caters to both research and clinical clients, primarily comprising pharmaceutical and biotechnology companies, as well as academic research institutions. These offerings support various stages of drug development, facilitate the analysis of clinical trials, and contribute to novel insights into human biology through the investigation of protein-protein and protein-gene interactions. Established in 1999, SomaLogic maintains its corporate headquarters in Boulder, Colorado.

Comparable companies

SomaLogic, Inc. is most often compared with the following Healthcare names:

ACCDCKPTCORBFCTEVGTHXORTXRVNCSHCRTRHCVIGL
More research on SLGC
SLGC technical analysis SLGC TheEdge Score Compare against peers
Open full interactive analysis & DCF →